Thierry Bernard spent 15 years in senior management at bioMérieux, one of the world’s top diagnostics companies. He was a member of the Executive Committee, and held roles as Strategy Director, head of Strategy and Clinical Marketing, Executive Vice President for the Europe/Middle East/Africa (EMEA) zone, and head of Global Customer Service. From 2007-2012, Thierry held the role of Senior Executive Vice-President, Global Commercial Operations, Sales, Marketing, Customer Service and Investor Relations out of Boston, where he directed the full P&L for €1.2 billion sales, marketing, and customer service for more than 3,000 global employees. He managed 42 subsidiaries and 130+ distributors worldwide. In 2012, he took on the role of expanding bioMérieux’s Operations in China. Thierry is a graduate of Sciences Po (Paris) and of Harvard Business School. He has a Master in Economy and Administration from the College of Europe and a Master of Science from the London School of Economics. He also has a degree in Foreign Trade (Barcelona) and is one of France’s Foreign Trade Advisors (Conseiller du Commerce Extérieur de la France).
Ed Roberts is Professor at the MIT Sloan School of Management, founder and chair of the MIT Entrepreneurship Center, and a prolific founder, investor and board member at numerous start-up companies in high technology. Ed’s portfolio of current and recent companies includes Advanced Magnetics, Inverness Medical, Meditech, Pegasystems, Sohu.com, and Visible Measures. He is the author of several books on technology and entrepreneurship, and holds four degrees from MIT, including a Ph.D. in Economics.
Bill Rodriguez is a co-founder and the CEO of Daktari Diagnostics.
David M. Rubin, Ph.D. is a Managing Director in Merck’s Global Health Innovation fund with a primary focus area on precision medicine. David has invested in molecular diagnostics, point-of-care diagnostics, imaging, and therapeutic device companies that address unmet needs in oncology, infectious disease, neurology, and cardiovascular disease. David holds board seats at OpGen, Daktari Diagnostics, electroCore, and Prophecy; and is a board observer at Asuragen and Genome Dx. David joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of all MRL disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. David joined Merck from Cognia Corporation where he was CEO and President, and helped to build it into one of the pioneer bioinformatics products company. Previously, David was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies. David holds a Ph.D. from Temple University in Molecular Biology and a BA from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Aaron Sandoski currently serves as the managing director at Norwich Ventures. Previously, Aaron worked for DEKA, the engineering think tank of Dean Kamen, where he helped develop partnerships and formulate business plans for emerging technologies. Aaron began his career as a consultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system. Aaron earned an M.B.A. from Harvard Business School and graduated from Dartmouth College with a double A.B. in Chemistry and Economics.